Literature DB >> 26845251

Indomethacin-Kollidon VA64 Extrudates: A Mechanistic Study of pH-Dependent Controlled Release.

Francesco Tres1, Kevin Treacher2, Jonathan Booth2, Leslie P Hughes2, Stephen A C Wren2, Jonathan W Aylott1, Jonathan C Burley1.   

Abstract

Because of its weakly acidic nature (pKa of 4.5), indomethacin presents an aqueous solubility that significantly increases when changing from acidic to neutral/alkaline pH (1.5 μg/mL at pH 1.2 and 105.2 μg/mL at pH 7.4). We have therefore investigated the impact of the dissolution medium pH on the dissolution performance of indomethacin:Kollidon VA64 extrudates. The impact of the drug loading on the dissolution properties of these systems was also examined (5%, 15%, 30%, 50%, 70%, and 90% drug loading). Time-resolved Raman spectroscopy along with in-line UV-vis spectrophotometry was employed to directly relate changes in dissolution behavior to physicochemical changes that occur to the extrudate during the test. The dissolution tests were performed in pH 2 HCl (to mimic the stomach conditions), and this was then switched during the experiment to pH 6.8 phosphate buffer (to simulate the poststomach conditions). The rotating disc dissolution rate test was also used to simultaneously measure the dissolution rate of both the drug and the polymer. We found that in pH 2 HCl buffer, for the 15% or higher drug-loaded extrudates, Kollidon VA64 preferentially dissolves from the exterior of the compact leaving an amorphous drug-rich hydrophobic shell, which, similarly to an enteric coating, inhibits the drug release. The in situ formation of an enteric coating has been previously hypothesized, and this has been the first time that is directly observed in a pH-variable dissolution test. The dissolution medium switch to pH 6.8 phosphate buffer, due to the large increase of the aqueous solubility of indomethacin at this pH, leads to rapid dissolution of the material forming the coating and therefore total drug release. In contrast, the 5% extrudate is fully hydrated and quickly dissolves at low pH pointing to a dissolution performance dependent on highly water-soluble Kollidon VA64.

Entities:  

Keywords:  UV−vis spectrophotometry; amorphous solid dispersions; hot melt extrusion; intrinsic dissolution rate; pH-variable dissolution; poorly soluble drugs; time-resolved Raman spectroscopy

Mesh:

Substances:

Year:  2016        PMID: 26845251     DOI: 10.1021/acs.molpharmaceut.5b00979

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  6 in total

Review 1.  Sustained-release amorphous solid dispersions.

Authors:  Julien Maincent; Robert O Williams
Journal:  Drug Deliv Transl Res       Date:  2018-12       Impact factor: 4.617

2.  Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues.

Authors:  Sai Prachetan Balguri; Goutham R Adelli; Soumyajit Majumdar
Journal:  Eur J Pharm Biopharm       Date:  2016-10-25       Impact factor: 5.571

Review 3.  The Need for Restructuring the Disordered Science of Amorphous Drug Formulations.

Authors:  Khadijah Edueng; Denny Mahlin; Christel A S Bergström
Journal:  Pharm Res       Date:  2017-05-18       Impact factor: 4.200

4.  Surface Stabilization and Dissolution Rate Improvement of Amorphous Compacts with Thin Polymer Coatings: Can We Have It All?

Authors:  Dunja Novakovic; Leena Peltonen; Antti Isomäki; Sara J Fraser-Miller; Line Hagner Nielsen; Timo Laaksonen; Clare J Strachan
Journal:  Mol Pharm       Date:  2020-02-25       Impact factor: 4.939

5.  Study of Physico-Chemical Properties and Morphology of Phospholipid Composition of Indomethacin.

Authors:  Elena G Tikhonova; Yulia A Tereshkina; Lyubov V Kostryukova; Yulia Yu Khudoklinova; Maxim A Sanzhakov; Anna O Tamarovskaya; Oleksandr I Ivankov; Mikhail A Kiselev
Journal:  Nanomaterials (Basel)       Date:  2022-07-25       Impact factor: 5.719

6.  Hybrid Nanobeads for Oral Indomethacin Delivery.

Authors:  Flávia Monique Rocha Bonetti; Eneida de Paula; Belchiolina Beatriz Fonseca; Gabriela Ribeiro da Silva; Leandro Santana Soares da Silva; Ludmilla David de Moura; Márcia Cristina Breitkreitz; Gustavo Henrique Rodrigues da Silva; Lígia Nunes de Morais Ribeiro
Journal:  Pharmaceutics       Date:  2022-03-08       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.